Evidence map›Paper›PMID 37792740›Full record

ArticlePloS one2023

Integration of serial self-testing for COVID-19 as part of contact tracing in the Brazilian public health system: A pragmatic trial protocol.

Rebecca K Green, Camilo Manchola, Emily Gerth-Guyette, Michelle Oliveira Silva, Raissa Stephanie, Tainá Dos Santos Soares, Luiza Bastos Gottin, Milena Coelho, Kimberly E Green, Alexandre Dias Tavares Costa and 1 more

Abstract readClinical Trial Protocol
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rebecca K GreenPATH, Seattle, Washington, United States of America.ORCID 0000-0002-4384-5324
Camilo MancholaGlobal Health Strategies, Rio de Janeiro, Rio de Janeiro, Brazil.
Emily Gerth-GuyettePATH, Seattle, Washington, United States of America.
Michelle Oliveira SilvaCentro de Pesquisa em Medicina Tropical de Rondônia (CEPEM), Porto Velho, Rondônia, Brazil.
Raissa StephanieCentro de Pesquisa em Medicina Tropical de Rondônia (CEPEM), Porto Velho, Rondônia, Brazil.
Tainá Dos Santos SoaresLaboratory for Applied Science and Technology in Health, Carlos Chagas Institute, Fiocruz Paraná, Curitiba, Paraná, Brazil.ORCID 0000-0001-6492-7815
Luiza Bastos GottinGlobal Health Strategies, Rio de Janeiro, Rio de Janeiro, Brazil.
Milena CoelhoGlobal Health Strategies, Rio de Janeiro, Rio de Janeiro, Brazil.
Kimberly E GreenPATH, Seattle, Washington, United States of America.
Alexandre Dias Tavares CostaLaboratory for Applied Science and Technology in Health, Carlos Chagas Institute, Fiocruz Paraná, Curitiba, Paraná, Brazil.ORCID 0000-0001-8434-2152
Dhélio Batista PereiraCentro de Pesquisa em Medicina Tropical de Rondônia (CEPEM), Porto Velho, Rondônia, Brazil.ORCID 0000-0002-7761-5498

Funding

Transform Dissemination and Implementation Science in CTSA ProgramsUL1TR002319 · NCATS · UNIVERSITY OF WASHINGTON · PI John K. Amory · 2017 to 2026
$100.0M
NCATS NIH HHS UL1 TR002319
6 · The paper itself

Abstract

The coronavirus disease (COVID-19) pandemic has led to an unprecedented public health crisis. Insufficient testing continues to limit the effectiveness of the global response to the COVID-19 pandemic. Molecular testing methods such as reverse transcriptase polymerase chain reaction (RT-PCR) continue to be highly centralized and are a sub-optimal option for population surveillance. Rapid antigen tests (Ag-RDTs) offer multiple benefits including low costs, high flexibility to conduct tests in a wide variety of settings, and faster return of results. Self-test Ag-RDTs (STs) have gained approval in several markets and offer the possibility to expand testing, reaching at-risk populations. While STs have the potential to assist the COVID-19 response, test result integrity, reporting, and appropriate linkage to care continue to hinder the widespread implementation of self-testing programs. This protocol presents a mixed-methods pragmatic trial (ISRCTN91602092) to better understand the feasibility of self-testing as part of a contact tracing strategy within the Brazilian public health system. Approximately 604 close contacts of 150 index cases testing positive for COVID-19 will be enrolled. Index cases will be randomized for their close contacts to participate in either serial (daily) self-testing over a 10-day follow-up period or a more traditional approach to contact tracing with a professional Ag-RDT at one time point post-exposure. Usability workshops and focus group discussions will also be conducted. This study protocol presents a comprehensive plan to assess the effectiveness, operational feasibility, and stakeholder preferences of a serial self-testing strategy for contact tracing within the Brazilian public health system. Our results will contribute to better understanding of the feasibility of a self-testing strategy within the public sector. Potential risks and limitations are discussed. Our findings will have important implications as governments continue working to mitigate the impact of COVID-19, particularly in the context of where to direct limited resources for testing and healthcare infrastructure. Registration: This trial is registered at ISCTRN (ISRCTN91602092).

Indexed as

COVID-19BrazilContact TracingCOVID-19 TestingHumansPandemicsPragmatic Clinical Trials as TopicPublic HealthSARS-CoV-2Self-Testing

Identifiers

PMID37792740
PMCPMC10550143

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.